Tamarind seeds join the fight against dry eye

Article

Tamarind seed polysaccharide (TSP) 0.5% and 1% offers at least equivalent relief from dry eye symptoms as hyaluronic acid (HA), according to a study published online by BMC Ophthalmology in March.

Tamarind seed polysaccharide (TSP) 0.5% and 1% offers at least equivalent relief from dry eye symptoms as hyaluronic acid (HA), according to a study published online by BMC Ophthalmology in March.

Maurizio Rolando and Cristiana Valente from the University of Genoa, Italy compared the activity of TSP and HA in an open-label, randomized, single centre clinical study. Thirty subjects were randomized to receive three or more applications per day of either TSP 0.5%, TSP 1% or HA 0.2% over a 90 day period. Tolerability was assessed by visual analogue scale (VAS).

TSP 0.5% and 1% were comparable to HA in terms of tolerability, stability of the pre-corneal tear film and corneal and conjunctival staining. However, TSP was found to be more beneficial than HA in terms of addressing subjective symptoms such as trouble blinking, ocular burning and foreign body sensation.

It was concluded that TSP is at least as effective against dry eye as HA and the authors suggest that larger studies are required to further establish the efficacy and safety of the compound as a treatment for dry eye syndrome.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.